ARGO trial Ph 2 RCT Sonelokimab IL-17A/Fi Nanobody Wk 12, primary ACR50 ACR 50 SON 120 mg 46% 60 mg 46% PBO 20% PASI 90 SON 120 mg 60% 60 mg 77% PBO 15% MDA SON 60mg 47% PBO 20% No new safety signal #EULAR2024 @RheumNow AbstrOP0195 https://t.co/4W5KFi23za